Bob Oranje

Oranje

Dr. Bob Oranje

  • psychoses
  • translational research
telefoon
+31 88 75 56003
email
B.Oranje-2@umcutrecht.nl

Biography

Bob Oranje obtained his PhD degree in Utrecht (2001) with René Kahn. In 2004 he was appointed senior researcher and head of the psychophysiological laboratory at the Center for Neuropsychiatric Schizophrenia Research (CNSR) and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), hosted by Glostrup Academic hospital, Denmark. In 2009 he was appointed Vice Chair of research of the CNSR and CINS, and appointed lector at at the Faculty of Health Sciences, Dept. of Neurology, Psychiatry, and Sensory Sciences of Copenhagen University. Since 2012 he is co-chair of the NICHE Laboratory, Department of Psychiatry, Brain Center Rudolf Magnus at the University Medical Center Utrecht. His primary line of research focuses on optimizing treatment of patients with schizophrenia, by  individualizing their medical treatment . In secondary lines he focuses among others on unraveling the affected neurotransmission in schizophrenia, translational research, the etiology of schizophrenia and gender related issues. In addition he  is involved in child and adolescent research on autism and ADHD. Central in his research is the Copenhagen Psychophysiological Test-Battery (the CPTB) that he specifically developed to study basic information processing in schizophrenia and other psychiatric disorders.

Research line and group

Research line
Schizophrenia
Number of PhD students
N=5
Number of postdocs
N=2

Personal fellowships and awards

  • Lundbeck foundation grants (main applicant personal salary 2009, 2010)
  • Lundbeck Foundation Center for Neurovascular signaling
  • Førskningsrådet for Sundhed of Sygdom (FSS) (co-applicant for postdoctoral researcher)
  • The Capital region of Psychiatry
  • Førskningsrådet for Sundhed of Sygdom

Most recent key publications

  • G. F. Madsen, N. Bilenberg, J. R. Jepsen, B. Y. Glenthøj, C. Cantio, and B. Oranje. Normal P50 gating in children with autism, yet attenuated P50 amplitude in the Asperger subcategory. Autism Res. Epub, 2015.
  • L. Witten, J. F. Bastlund, B. Y. Glenthoj, C. Bundgaard, B. Steiniger-Brach, A. Mork, and B. Oranje. Comparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol. Neuropsychopharmacology, 2015.
  • N. Bak and B. Oranje. Psychophysiology-Informed (Multimodal) Imaging. Curr.Top.Behav.Neurosci. 21:371-385, 2014.
  • S. During, B. Y. Glenthoj, G. S. Andersen, and B. Oranje. Effects of Dopamine D2/D3 Blockade on Human Sensory and Sensorimotor gating in Initially Antipsychotic-Naive, First-Episode Schizophrenia Patients. Neuropsychopharmacology E-pub, 2014
  • N. Bak, E. Rostrup, H. B. Larsson, B. Y. Glenthoj, and B. Oranje. Concurrent functional magnetic resonance imaging and electroencephalography assessment of sensory gating in schizophrenia. Hum.Brain Mapp., 2013.